Drug Profile
Atorvastatin/losartan - HanAll Biopharma
Alternative Names: HL-040; HL-040XC; Immediate release atorvastatin/delayed release losartan potassium - HanAll Biopharma; Losartan potassium/atorvastatin Ca - HanAll Biopharma; YH-IMD1Latest Information Update: 25 Feb 2021
Price :
$50
*
At a glance
- Originator HanAll Biopharma
- Developer HanAll Biopharma; Yuhan
- Class Amides; Antihyperlipidaemics; Antihypertensives; Biphenyl compounds; Fatty acids; Fluorobenzenes; Heart failure therapies; Heptanoic acids; Imidazoles; Ischaemic heart disorder therapies; Pyrroles; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Hyperlipidaemia; Hypertension
Most Recent Events
- 25 Feb 2021 No development reported - Phase-III for Hyperlipidaemia in USA (PO) (HanAll Biopharma pipeline, February 2021)
- 25 Feb 2021 No development reported - Phase-III for Hypertension in USA (PO) (HanAll Biopharma pipeline, February 2021)
- 16 Oct 2017 Chemical structure information added